Policies and actions to tackle rare diseases at European level


Antoni Montserrat and Domenica Taruscio

Rare diseases (RDs) are defined by the European Union as life-threatening or chronically debilitating conditions, with a prevalence lower than 5 per 10 000 inhabitants. Around
6000 diseases are described, affecting between 6% and 8% of the European population.
Due to their severity, diffusion and multi-faceted aspects, RD are an area where collaboration in public health, health care and research provides a major integrated added value.
Main areas for policy actions include: the development and implementation of European
Reference Networks, as a main strategy for sharing of knowledge, clinical expertise and
foster research; integration of high-quality patient registries, biobanks, and bioinformatics support, as key infrastructure tools addressing research and healthcare needs; the
implementation of National Plans on RD in EU Member States by sharing experiences,
capacity building and linking national efforts through a common strategy at a European level; actions driven by the recommendations for primary prevention of congenital
anomalies (the main RD group with multifactorial aetiology); policy provisions to foster
research and development of orphan drugs.

Published: 4 October 2019
Journal: Ann Ist Super Sanità 2019, volume 55, issue 3, pages 296-304

Link: doi.org/10.4415/ANN_19_03_17

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern